Insider Trading Activity Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) – Major Shareholder Bought 15,000 shares of Stock

0

Insider Trading Activity For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

Michael Rapp , Major Shareholder of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reportedly Bought 15,000 shares of the company’s stock at an average price of 12.99 for a total transaction amount of $194,850.00 SEC Form

Insider Trading History For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

  • On 8/16/2016 Suzanne M Hanlon, Insider, sold 3,000 with an average share price of $10.53 per share and the total transaction amounting to $31,590.00.View SEC Filing
  • On 12/7/2016 James E Fickenscher, CFO, bought 7,000 with an average share price of $14.08 per share and the total transaction amounting to $98,560.00.View SEC Filing
  • On 12/29/2016 Michael Rapp, Major Shareholder, bought 10,000 with an average share price of $15.85 per share and the total transaction amounting to $158,500.00.View SEC Filing
  • On 5/12/2017 James E Fickenscher, CFO, bought 5,200 with an average share price of $19.82 per share and the total transaction amounting to $103,064.00.View SEC Filing
  • On 5/15/2017 Armando Anido, Chairman, bought 5,000 with an average share price of $19.70 per share and the total transaction amounting to $98,500.00.View SEC Filing
  • On 10/19/2017 Michael Rapp, Major Shareholder, bought 44,255 with an average share price of $9.59 per share and the total transaction amounting to $424,405.45.View SEC Filing
  • On 10/23/2017 Michael Rapp, Major Shareholder, bought 25,745 with an average share price of $9.94 per share and the total transaction amounting to $255,905.30.View SEC Filing
  • Analyst Ratings History For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

    • On 8/14/2017 Maxim Group Reiterated Rating Hold
    • On 8/15/2017 Jefferies Group Downgraded rating Buy to Hold with a price target of $12.00 to $7.00
    • On 8/15/2017 HC Wainwright Set Price Target of rating Hold with a price target of $7.00
    • On 8/15/2017 CIBC Reiterated Rating Outperform to Market Perform
    • On 10/1/2017 Roth Capital Set Price Target of rating Buy with a price target of $15.00 with a price target of $16.00 to $20.00
    • On 11/14/2017 Oppenheimer Reiterated Rating Hold

    Recent Trading Activity for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)
    Shares of Zynerba Pharmaceuticals Inc closed the previous trading session at 13.00 +0.00 0.00% with 13.130000114440918 shares trading hands.